Search IPOs
Grey Market Premium · Dec 08 – Dec 10, 2025 · Issue Price ₹1,062
Corona Remedies IPO GMP: ₹342.50 — 32.3% expected gain as of Dec 15, 2025
The Corona Remedies IPO Grey Market Premium (GMP) is currently trading at ₹342.50 in the unofficial grey market. Based on this, the expected listing price is ₹1,404.50, implying a +32.3% gain over the issue price of ₹1,062. GMP reflects pre-listing demand from grey market participants and is a widely tracked sentiment indicator among IPO investors.
Grey market premium over time (₹)
Latest 5 data points, most recent first
| Date / Time | GMP (₹) | Exp. Listing | Exp. Gain |
|---|---|---|---|
| Dec 15, 2025 1:04 pm | +₹342.50 | ₹1,404.50 | +32.3% |
| Dec 11, 2025 2:35 pm | +₹291.00 | ₹1,353.00 | +27.4% |
| Dec 10, 2025 6:02 pm | +₹295.00 | ₹1,357.00 | +27.8% |
| Dec 09, 2025 4:15 pm | +₹270.00 | ₹1,332.00 | +25.4% |
| Dec 08, 2025 4:00 pm | +₹262.00 | ₹1,324.00 | +24.7% |
The Corona Remedies IPO GMP (Grey Market Premium) is the unofficial pre-listing price at which shares trade in informal markets before the IPO is listed on the stock exchange. Currently, the Corona Remedies IPO GMP stands at ₹342.50, implying an expected listing price of ₹1,404.50.
GMP = Expected Listing Price − Issue Price. If the issue price of Corona Remedies IPO is ₹1,062 and the expected listing is ₹1,404.50, then GMP = ₹342.50. The expected gain percentage is calculated as (GMP ÷ Issue Price) × 100. For Corona Remedies IPO, that is 32.3%.
GMP is not regulated by SEBI and reflects informal market activity. It can fluctuate significantly day-to-day and should not be the sole basis for investment decisions. Many IPOs with high GMP have listed below expectations, and vice versa. Always refer to subscription data, financials, and the DRHP before investing.
We classify GMP signals as: Hot (expected gain ≥30%), Warm (10–30%), Neutral (0–10%), and Weak (negative GMP). Corona Remedies IPO is currently classified as Hot.
The current Grey Market Premium for Corona Remedies IPO is ₹342.50 as of Dec 15, 2025. Expected listing price: ₹1,404.50, expected gain: 32.3%. GMP data is updated periodically from grey market sources.
A GMP of ₹342.50 means that in the unofficial grey market, Corona Remedies IPO shares are trading at ₹342.50 above the issue price. With an issue price of ₹1,062, this implies an expected listing at ₹1,404.50 (32.3% gain). GMP is purely indicative and actual listing price depends on market conditions.
GMP is an unofficial, unregulated indicator from the informal grey market. It reflects speculative pre-listing demand but can be manipulated or change rapidly. Use it as one data point alongside official subscription data, company financials, and valuation metrics. SEBI does not regulate grey market trading.
Kostak rate data for Corona Remedies IPO will be available once reported from grey market sources. Kostak represents the per-application premium in informal markets.
Corona Remedies IPO is expected to list on December 15, 2025 on NSE,BSE. The GMP on listing day is a strong short-term indicator of opening price.
GMP is unofficial and unregulated. Past GMP accuracy varies. Use alongside subscription data and fundamentals.